261 related articles for article (PubMed ID: 28453889)
1. Discrepant platelet and plasma von Willebrand factor in von Willebrand disease patients with p.Pro2808Leufs*24.
Bowman ML; Pluthero FG; Tuttle A; Casey L; Li L; Christensen H; Robinson KS; Lillicrap D; Kahr WHA; James P
J Thromb Haemost; 2017 Jul; 15(7):1403-1411. PubMed ID: 28453889
[TBL] [Abstract][Full Text] [Related]
2. Clinical and laboratory phenotype variability in type 2M von Willebrand disease.
Doruelo AL; Haberichter SL; Christopherson PA; Boggio LN; Gupta S; Lentz SR; Shapiro AD; Montgomery RR; Flood VH
J Thromb Haemost; 2017 Aug; 15(8):1559-1566. PubMed ID: 28544236
[TBL] [Abstract][Full Text] [Related]
3. The genetics of Canadian type 3 von Willebrand disease: further evidence for co-dominant inheritance of mutant alleles.
Bowman M; Tuttle A; Notley C; Brown C; Tinlin S; Deforest M; Leggo J; Blanchette VS; Lillicrap D; James P;
J Thromb Haemost; 2013 Mar; 11(3):512-20. PubMed ID: 23311757
[TBL] [Abstract][Full Text] [Related]
4. von Willebrand factor propeptide variants lead to impaired storage and ER retention in patient-derived endothelial colony-forming cells.
Bowman M; Casey L; Selvam SN; Lima PDA; Rawley O; Hinds M; Tuttle A; Grabell J; Iorio A; Walker I; Lillicrap D; James P
J Thromb Haemost; 2022 Jul; 20(7):1599-1609. PubMed ID: 35466528
[TBL] [Abstract][Full Text] [Related]
5. Angiogenic characteristics of blood outgrowth endothelial cells from patients with von Willebrand disease.
Groeneveld DJ; van Bekkum T; Dirven RJ; Wang JW; Voorberg J; Reitsma PH; Eikenboom J
J Thromb Haemost; 2015 Oct; 13(10):1854-66. PubMed ID: 26270243
[TBL] [Abstract][Full Text] [Related]
6. Type 2M:Milwaukee-1 von Willebrand disease: an in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to platelets.
Mancuso DJ; Kroner PA; Christopherson PA; Vokac EA; Gill JC; Montgomery RR
Blood; 1996 Oct; 88(7):2559-68. PubMed ID: 8839848
[TBL] [Abstract][Full Text] [Related]
7. Cellular and molecular basis of von Willebrand disease: studies on blood outgrowth endothelial cells.
Starke RD; Paschalaki KE; Dyer CE; Harrison-Lavoie KJ; Cutler JA; McKinnon TA; Millar CM; Cutler DF; Laffan MA; Randi AM
Blood; 2013 Apr; 121(14):2773-84. PubMed ID: 23355534
[TBL] [Abstract][Full Text] [Related]
8. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis.
Casonato A; Sartorello F; Pontara E; Gallinaro L; Bertomoro A; Grazia Cattini M; Daidone V; Szukowska M; Pagnan A
Thromb Haemost; 2007 Dec; 98(6):1182-7. PubMed ID: 18064311
[TBL] [Abstract][Full Text] [Related]
9. Clinically relevant differences between assays for von Willebrand factor activity.
Boender J; Eikenboom J; van der Bom JG; Meijer K; de Meris J; Fijnvandraat K; Cnossen MH; Laros-van Gorkom BAP; van Heerde WL; Mauser-Bunschoten EP; de Maat MPM; Leebeek FWG;
J Thromb Haemost; 2018 Dec; 16(12):2413-2424. PubMed ID: 30358069
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the storage and secretion of von Willebrand factor in blood outgrowth endothelial cells derived from patients with von Willebrand disease.
Wang JW; Bouwens EA; Pintao MC; Voorberg J; Safdar H; Valentijn KM; de Boer HC; Mertens K; Reitsma PH; Eikenboom J
Blood; 2013 Apr; 121(14):2762-72. PubMed ID: 23426949
[TBL] [Abstract][Full Text] [Related]
11. The impact of aberrant von Willebrand factor-GPIbα interaction on megakaryopoiesis and platelets in humanized type 2B von Willebrand disease model mouse.
Kanaji S; Morodomi Y; Weiler H; Zarpellon A; Montgomery RR; Ruggeri ZM; Kanaji T
Haematologica; 2022 Sep; 107(9):2133-2143. PubMed ID: 35142156
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a microfluidic flow assay to screen for von Willebrand disease and low von Willebrand factor levels.
Lehmann M; Ashworth K; Manco-Johnson M; Di Paola J; Neeves KB; Ng CJ
J Thromb Haemost; 2018 Jan; 16(1):104-115. PubMed ID: 29064615
[TBL] [Abstract][Full Text] [Related]
13. von Willebrand factor binds to platelets and induces aggregation in platelet-type but not type IIB von Willebrand disease.
Miller JL; Kupinski JM; Castella A; Ruggeri ZM
J Clin Invest; 1983 Nov; 72(5):1532-42. PubMed ID: 6415113
[TBL] [Abstract][Full Text] [Related]
14. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of platelet-inspired hemostatic nanoparticles on bleeding in von Willebrand disease murine models.
Roullet S; Luc N; Rayes J; Solarz J; Disharoon D; Ditto A; Gahagan E; Pawlowski C; Sefiane T; Adam F; Casari C; Christophe OD; Bruckman M; Lenting PJ; Sen Gupta A; Denis CV
Blood; 2023 Jun; 141(23):2891-2900. PubMed ID: 36928925
[TBL] [Abstract][Full Text] [Related]
16. Platelet von Willebrand factor determination does not improve the diagnosis of patients with suspected Type 1 von Willebrand disease.
Shihong I; Morris D; Konkle BA
Haemophilia; 2009 Jan; 15(1):131-4. PubMed ID: 18976254
[TBL] [Abstract][Full Text] [Related]
17. Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor.
Eikenboom JC; Matsushita T; Reitsma PH; Tuley EA; Castaman G; Briët E; Sadler JE
Blood; 1996 Oct; 88(7):2433-41. PubMed ID: 8839833
[TBL] [Abstract][Full Text] [Related]
18. Whole blood ristocetin-induced platelet impedance aggregometry does not reflect clinical severity in patients with type 1 von Willebrand disease.
Nakajima Y; Nogami K; Yada K; Ogiwara K; Furukawa S; Shimonishi N; Shima M
Haemophilia; 2019 May; 25(3):e174-e179. PubMed ID: 30866149
[TBL] [Abstract][Full Text] [Related]
19. Unraveling the Influence of Common von Willebrand factor variants on von Willebrand Disease Phenotype: An Exploratory Study on the Molecular and Clinical Profile of von Willebrand Disease in Spain Cohort.
Borràs N; Garcia-Martínez I; Batlle J; Pérez-Rodríguez A; Parra R; Altisent C; López-Fernández MF; Costa Pinto J; Batlle-López F; Cid AR; Bonanad S; Cabrera N; Moret A; Mingot-Castellano ME; Navarro N; Pérez-Montes R; Marcellini S; Moreto A; Herrero S; Soto I; Fernández-Mosteirín N; Jiménez-Yuste V; Alonso N; de Andrés-Jacob A; Fontanes E; Campos R; Paloma MJ; Bermejo N; Berrueco R; Mateo J; Arribalzaga K; Marco P; Palomo Á; Castro Quismondo N; Iñigo B; Del Mar Nieto M; Vidal R; Martínez MP; Aguinaco R; Tenorio M; Ferreiro M; García-Frade J; Rodríguez-Huerta AM; Cuesta J; Rodríguez-González R; García-Candel F; Dobón M; Aguilar C; Corrales I; Vidal F
Thromb Haemost; 2020 Mar; 120(3):437-448. PubMed ID: 32135566
[TBL] [Abstract][Full Text] [Related]
20. Homozygous type 2N R854W von Willebrand factor is poorly secreted and causes a severe von Willebrand disease phenotype.
Castaman G; Giacomelli SH; Jacobi P; Obser T; Budde U; Rodeghiero F; Haberichter SL; Schneppenheim R
J Thromb Haemost; 2010 Sep; 8(9):2011-6. PubMed ID: 20586924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
